Ardelyx Inc., ARDX Quick Chart - (NAS) ARDX, Ardelyx Inc ... Ardelyx stock price target raised to $16 from $14 at Wedbush MarketWatch. Wednesday, October 11, 2017. Industry Analysis & Forecast to 2026 AmericaNewsHour. Friday, March 06, 2020. 04:02 PM ET. Ardelyx Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights PR Newswire - … Work With Us | Ardelyx work with us We are committed to scientific and clinical integrity and a passionate pursuit of medical innovation to deliver highest-quality medicines to improve … STOCK INFO | Ardelyx, Inc. The Investor Relations website contains information about Ardelyx, Inc.'s business for stockholders, potential investors, and financial analysts. ARDX Stock | ARDELYX Stock Price Today | Markets Insider
Sep 4, 2019 So it is little wonder that Ardelyx's stock jumped 71% yesterday on the data Currently, EvaluatePharma sellside consensus forecasts higher
Ardelyx Inc. Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of cardiorenal diseases. Ardelyx, Inc. Common Stock (ARDX) Stock Quotes | Nasdaq Ardelyx, Inc. Common Stock (ARDX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Ardelyx Ardelyx to Participate in Leerink Partners 8th Annual Global Healthcare Conference. Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference at… ARDX: Ardelyx Inc - Stock Price, Quote and News - CNBC Get Ardelyx Inc (ARDX:NASDAQ) real-time stock quotes, news and financial information from CNBC.
Get Ardelyx Inc (ARDX:NASDAQ) real-time stock quotes, news and financial information from CNBC.
Ardelyx - ARDX - Stock Price & News | The Motley Fool Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium ARDX Stock Price and Chart — NASDAQ:ARDX — TradingView Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of cardiorenal diseases. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. Ardelyx (ARDX) Reports Q4 Loss, Tops Revenue Estimates ... Ahead of this earnings release, the estimate revisions trend for Ardelyx was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock.